Literature DB >> 23629485

Bone marrow-derived mesenchymal stem cell transplantation for chronic spinal cord injury in rats: comparative study between intralesional and intravenous transplantation.

Jang-Woon Kim1, Kee-Yong Ha, Jan Noel Molon, Young-Hoon Kim.   

Abstract

STUDY
DESIGN: Animal experimental study.
OBJECTIVE: To present experimental evidence for mesenchymal cell therapy for spinal cord injury (SCI). SUMMARY OF BACKGROUND DATA: Prior to clinical application of stem cell therapy for SCI, many critical issues have to be addressed including efficiency, safety, method of transplantation, and differentiation of the transplanted cells.
METHODS: Chronic contusive SCI was induced in 36 Sprague-Dawley rats and randomly assigned to the intralesional (IL), intravenous (IV), or control groups. At 6 weeks post injury, allogenic mesenchymal stem cells (MSCs, 1 × 10 cells) were transplanted either intralesionally or intravenously for the intervention groups. Engraftment of the transplanted MSCs was evaluated with PKH 26 staining. Differentiation was evaluated using double stain with neuronal and glial cell markers. Brain-derived neurotrophic factor and nerve growth factor (NGF) were used for neurotrophic factor expression. Basso, Beattie, and Bresnahan locomotor rating scale was used for evaluation of functional recovery.
RESULTS: The estimated engraftment percentage of the transplanted cells in the IL group and IV group were 36.5%, and 15.5%, respectively. The engraftment of the transplanted MSCs was higher in the IL group than in the IV group. Most of the transplanted MSCs were colocalized with GFAP in both transplantation groups. Brain-derived neurotrophic factor and NGF expression (Western blot and real-time polymerase chain reaction) in the injured spinal cord was higher in both transplanted groups compared with those in the control group. At 6 weeks post transplantation, the mean Basso, Beattie, and Bresnahan locomotor scales in the IL, IV, and control groups were 5.63 ± 0.89, 5.63 ± 1.03, and 2.88 ± 0.44, respectively. The functional recovery seen in the rats that underwent transplantation was significantly better than that in the control group (P < 0.05).
CONCLUSION: Although the number of engrafted cells and expression of neurotrophic factors were lower in the IV group than those in the IL group, both IL and IV transplantation of MSC in the chronic SCI gave a significant clinical improvement. However, there were no differences in differentiation of the transplanted cells between the IL group and IV group. Astrocytic differentiation of the transplanted cells was predominant. LEVEL OF EVIDENCE: N/A.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23629485     DOI: 10.1097/BRS.0b013e31829839fa

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  33 in total

1.  Magnetic resonance and photoacoustic imaging of brain tumor mediated by mesenchymal stem cell labeled with multifunctional nanoparticle introduced via carotid artery injection.

Authors:  Yang Qiao; Joy Gumin; Christopher J MacLellan; Feng Gao; Richard Bouchard; Frederick F Lang; R Jason Stafford; Marites P Melancon
Journal:  Nanotechnology       Date:  2018-04-20       Impact factor: 3.874

Review 2.  Neurotrauma and mesenchymal stem cells treatment: From experimental studies to clinical trials.

Authors:  Ana Maria Blanco Martinez; Camila de Oliveira Goulart; Bruna Dos Santos Ramalho; Júlia Teixeira Oliveira; Fernanda Martins Almeida
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

Review 3.  Concise Review: Bridging the Gap: Novel Neuroregenerative and Neuroprotective Strategies in Spinal Cord Injury.

Authors:  Christopher S Ahuja; Michael Fehlings
Journal:  Stem Cells Transl Med       Date:  2016-04-29       Impact factor: 6.940

4.  Spinal cord injury in rats treated using bone marrow mesenchymal stem-cell transplantation.

Authors:  Yu-Bing Chen; Quan-Zhang Jia; Dong-Jun Li; Jing-Hai Sun; Shuang Xi; Li-Ping Liu; De-Xuan Gao; Da-Wei Jiang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

5.  Mild hypothermia combined with a scaffold of NgR-silenced neural stem cells/Schwann cells to treat spinal cord injury.

Authors:  Dong Wang; Jinhua Liang; Jianjun Zhang; Shuhong Liu; Wenwen Sun
Journal:  Neural Regen Res       Date:  2014-12-15       Impact factor: 5.135

6.  Dexamethasone and azathioprine promote cytoskeletal changes and affect mesenchymal stem cell migratory behavior.

Authors:  Natália Schneider; Fabiany da Costa Gonçalves; Fernanda Otesbelgue Pinto; Patrícia Luciana da Costa Lopez; Anelise Bergmann Araújo; Bianca Pfaffenseller; Eduardo Pandolfi Passos; Elizabeth Obino Cirne-Lima; Luíse Meurer; Marcelo Lazzaron Lamers; Ana Helena Paz
Journal:  PLoS One       Date:  2015-03-10       Impact factor: 3.240

Review 7.  Cell therapy and delivery strategies for spinal cord injury.

Authors:  Bruna Dos S Ramalho; Fernanda M de Almeida; Ana M B Martinez
Journal:  Histol Histopathol       Date:  2021-06-10       Impact factor: 2.303

8.  Bone marrow stromal cells inhibit caspase-12 expression in rats with spinal cord injury.

Authors:  Wei Liu; Yueming Ding; Xiaoming Zhang; Linlin Wang
Journal:  Exp Ther Med       Date:  2013-07-04       Impact factor: 2.447

9.  Tissue engineering is a promising method for the repair of spinal cord injuries (Review).

Authors:  Wenchen Ji; Shouye Hu; Jiao Zhou; Gang Wang; Kunzheng Wang; Yuelin Zhang
Journal:  Exp Ther Med       Date:  2013-12-18       Impact factor: 2.447

Review 10.  Managing inflammation after spinal cord injury through manipulation of macrophage function.

Authors:  Yi Ren; Wise Young
Journal:  Neural Plast       Date:  2013-10-31       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.